argenex (NASDAQ:ARGX) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis

argenex (NASDAQ:ARGX) and Voyager Therapeutics (NASDAQ:VYGR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for argenex and Voyager Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0	6	21	1	2.82
Voyager Therapeutics	1	0	1	1	2.67

argenex currently has a consensus price target of $1,158.76, indicating a potential upside of 18.08%. Voyager Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,370.59%. Given Voyager Therapeutics’ higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than argenex.

Earnings and Valuation

This table compares argenex and Voyager Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25 billion	14.53	$1.29 billion	$28.66	34.24
Voyager Therapeutics	$40.37 million	2.62	-$119.72 million	($1.73)	-0.98

argenex has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

argenex has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares argenex and Voyager Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
argenex	31.66%	47.70%	40.12%
Voyager Therapeutics	-416.32%	-63.42%	-49.40%

Institutional and Insider Ownership

60.3% of argenex shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

argenex beats Voyager Therapeutics on 10 of the 13 factors compared between the two stocks.

About argenex

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

About Voyager Therapeutics

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.